Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.36 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.36 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916952 | 0.86 | PDE11A (0.42) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL3027474 | 0.76 | CHRNA10 (0.37) | KMT2AMEN1ALDH1A1KDM4EPDE11A | |
| SCHEMBL13212450 | 0.69 | ALDH1A1 (0.40) | KMT2AMEN1ALDH1A1KDM4EHPGD | |
| SCHEMBL2919900 | 0.67 | LMNA (0.42) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL2920700 | 0.67 | HTR2C (0.55) | MAPTNPC1 | |
| SCHEMBL2918582 | 0.67 | MAPT (0.49) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL13211470 | 0.66 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL6501140 | 0.66 | KDM4E (0.67) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL32688379 | 0.65 | ALDH1A1 (0.80) | KMT2AMEN1ALDH1A1HSD17B10GAA | |
| SCHEMBL29631156 | 0.64 | ALDH1A1 (0.73) | KMT2AMEN1ALDH1A1HSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354531-B2 | Compounds for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-15 | — | — | US | disclosed |
| EP-1874781-B9 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2010-09-08 | — | — | EP | disclosed |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
| US-7723341-B2 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2010-05-25 | — | — | US | disclosed |
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| EP-1874781-B1 | DIHYDROTHIENOPYRIMIDINES FOR THE TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2009-06-24 | — | — | EP | disclosed |
| EP-2060575-A1 | Dihydrothienopyrimidines and their use in treating inflammatory diseases | Boehringer Ingelheim International GmbH (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7511045-B2 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-31 | — | — | US | disclosed |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186875-A1 | Dihydrothienopyrimidines, suitable for the treatment of respiratory, gastrointestinal, inflammatory, nervous system disorders and/or cancer | DPYD, DHODH, FH | KMT2A 4426/4885MEN1 2282/4885ALDH1A1 47/4885 |
| US-20100197656-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES | TPMT, MALT1, IL1B | KMT2A 4617/4885MEN1 2098/4885ALDH1A1 100/4885 |
| US-20070259846-A1 | Dihydrothienopyrimidines; gastrointestinal disorders; cancer | DPYD, DHODH, DPM1 | KMT2A 4444/4885MEN1 2070/4885ALDH1A1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.